Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of CPIX opened at $1.12 on Friday. Cumberland Pharmaceuticals has a 1-year low of $1.07 and a 1-year high of $2.36. The firm has a market capitalization of $15.79 million, a price-to-earnings ratio of -1.53 and a beta of 0.20. The company has a 50-day moving average of $1.27 and a 200 day moving average of $1.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.44 and a quick ratio of 1.26.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.